Many anticancer agents function by targeting specific molecules involved in the proliferation and survival of cancer cells, while sparing normal cells. However, the unknown binding targets or unintended off-targets of these drugs often result in less effective treatments and lower patient survival rates. This knowledge gap also hinders the advancement of more efficacious cancer therapies. In response to this challenge, Dr. Wu's team has innovated in identifying the binding targets of anticancer drugs, facilitating a deeper understanding of their mechanisms. Moreover, they have formulated cost-effective, safe methodologies for screening aptamer-based therapeutics for cancer treatment. To sup...
Read More
Many anticancer agents function by targeting specific molecules involved in the proliferation and survival of cancer cells, while sparing normal cells. However, the unknown binding targets or unintended off-targets of these drugs often result in less effective treatments and lower patient survival rates. This knowledge gap also hinders the advancement of more efficacious cancer therapies. In response to this challenge, Dr. Wu's team has innovated in identifying the binding targets of anticancer drugs, facilitating a deeper understanding of their mechanisms. Moreover, they have formulated cost-effective, safe methodologies for screening aptamer-based therapeutics for cancer treatment. To support this breakthrough work and serve researchers across Texas in drug target identification and therapeutic aptamer development, we propose establishing the Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core. This initiative is driven by the demonstrated interest of numerous Texas-based researchers focused on developing effective anticancer drugs. These researchers foresee the CATDAD Core as a pivotal resource for identifying critical drug binding partners, expediting their research in cancer drug discovery. Significantly, pinpointing drug binding targets not only streamlines the development of effective therapies but also aids in differentiating patients who would benefit from specific treatments, thus avoiding ineffectual therapies and minimizing adverse effects. Our services aim to create a robust foundation for pioneering drug development and application in oncology. Baylor Scott and White Health has demonstrated a steadfast commitment to fostering the CATDAD Core, acknowledging its potential to revolutionize cancer research and patient care. This facility, unique in its integration within a clinical setting in Temple, central Texas, represents a significant stride in cancer treatment innovation.
Read Less
|
